ES2061638T3 - Purificacion de lfa-3. - Google Patents

Purificacion de lfa-3.

Info

Publication number
ES2061638T3
ES2061638T3 ES88301709T ES88301709T ES2061638T3 ES 2061638 T3 ES2061638 T3 ES 2061638T3 ES 88301709 T ES88301709 T ES 88301709T ES 88301709 T ES88301709 T ES 88301709T ES 2061638 T3 ES2061638 T3 ES 2061638T3
Authority
ES
Spain
Prior art keywords
lfa
purification
quantify
purifying
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301709T
Other languages
English (en)
Inventor
Michael Dustin
Timothy Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2061638T3 publication Critical patent/ES2061638T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Removal Of Specific Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO PARA PURIFICAR LFA-3 QUE EMPLEA CROMATOGRAFIA DE AFINIDAD. LA LFA-3 PURIFICADA ES UTIL PARA CUANTIFICAR O SEPARAR CELULAS QUE CONTIENEN CD-2.
ES88301709T 1987-02-26 1988-02-26 Purificacion de lfa-3. Expired - Lifetime ES2061638T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1901087A 1987-02-26 1987-02-26

Publications (1)

Publication Number Publication Date
ES2061638T3 true ES2061638T3 (es) 1994-12-16

Family

ID=21790939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301709T Expired - Lifetime ES2061638T3 (es) 1987-02-26 1988-02-26 Purificacion de lfa-3.

Country Status (6)

Country Link
EP (1) EP0280578B1 (es)
JP (1) JPS63276494A (es)
AT (1) ATE98649T1 (es)
CA (1) CA1326940C (es)
DE (1) DE3886237T2 (es)
ES (1) ES2061638T3 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
JPH02262599A (ja) * 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
ATE184049T1 (de) * 1990-07-20 1999-09-15 Bayer Ag Multimere formen des menschlichen rhinovirus- rezeptorproteins
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
WO1992016563A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Monoclonal antibodies recognizing lymphocyte function associated antigen-3
DE69232295T2 (de) * 1991-10-07 2002-07-18 Biogen, Inc. Verfahren zur Verbesserung der Toleranz für Allotransplantaten und Xenotransplantaten durch Verabreichung eines LFA-3- oder CD2-Bindungsproteins
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
EP1750747A1 (en) 2004-05-07 2007-02-14 Astellas US LLC Soluble lfa-3 polypeptide for treating viral disorders
BR112017018365A2 (pt) * 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas

Also Published As

Publication number Publication date
EP0280578B1 (en) 1993-12-15
ATE98649T1 (de) 1994-01-15
CA1326940C (en) 1994-02-08
EP0280578A3 (en) 1989-03-29
DE3886237T2 (de) 1994-05-05
EP0280578A2 (en) 1988-08-31
JPS63276494A (ja) 1988-11-14
DE3886237D1 (de) 1994-01-27

Similar Documents

Publication Publication Date Title
ES2061642T3 (es) Metodo para la purificacion del factor viii:c de una mezcla de polipeptidos y otros constituyentes.
AU569129B2 (en) Factor viii:c purification
ES2155477T3 (es) Purificacion cromatografica y procedimiento de separacion de acidos nucleicos.
ATE114172T1 (de) Reinigungsverfahren für antikörper.
DE3886237D1 (de) Reinigung von LFA-3.
ZA864697B (en) Purification of hemoglobin by affinity chromatography
EP0208215A3 (en) Purification of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
ZA818730B (en) Recycle of hydrogenated sulphur plant tail gas to sour gas scrubbing system
ATE54938T1 (de) Verfahren zur reinigung des japanischen enzephalitisvirus.
ES2048427T3 (es) Purificacion de acido isoftalico en bruto.
ZA864660B (en) High performance liquid chromatography mobile phase
ES526195A0 (es) Procedimiento de purificacion de soluciones acuosas uraniferas que contienen impurezas
EP0152346A3 (en) Method for purifying gamma-interferon
ATE76082T1 (de) Reinigungsmethode fuer antikoerper.
ES539710A0 (es) Un proceso para la purificacion de soluciones que contengan fructosa 2-6 difosfato
FR2549041B1 (fr) Procede de purification de 4-fluorophenol
BE861412A (fr) Procede de purification de l'anthraquinone brute
FI841591A7 (fi) Menetelmä puhdistettavan nesteen puhdistamiseksi flotaatioselkeytyksen avulla.
FR2572952B1 (fr) Procede et installation de purification des fumees
BE883070A (fr) Procede pour la purification de caprolactame brut contenant des amides primaires et caprolactame purifie obtenu
DE3062880D1 (en) Apoglucose oxidase preparation and its production
MY102245A (en) Purification of antibodies
DK184685A (da) Fenoldopam-4',8-bis-hydrogensulfater, fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende disse
RO92831A2 (ro) Procedeu de purificare a polietilenglicolilor
RO89827A2 (ro) Procedeu de purificare a p-etoxiacetanilidei

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 280578

Country of ref document: ES